过去几年，中国创新药产业经历了“高投入、低回报”的考验期。2025年起，随着医保支付体系优化、商业保险基金加速进入、监管审批提效，产业环境逐渐改善，市场关注点从单纯的估值修复转向业绩兑现。在资本和政策的共同作用下，越来越多的Biotech企业开始呈现出清晰的盈利路径。在这样的背景下，百奥赛图（02315.HK）最新披露的半年报，成为行业的一次标志性事件：它不仅在财务层面交出了扭亏为盈的答卷，更在...
Source Link过去几年，中国创新药产业经历了“高投入、低回报”的考验期。2025年起，随着医保支付体系优化、商业保险基金加速进入、监管审批提效，产业环境逐渐改善，市场关注点从单纯的估值修复转向业绩兑现。在资本和政策的共同作用下，越来越多的Biotech企业开始呈现出清晰的盈利路径。在这样的背景下，百奥赛图（02315.HK）最新披露的半年报，成为行业的一次标志性事件：它不仅在财务层面交出了扭亏为盈的答卷，更在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.